Blue Horseshoe Stocks: CNAT, Options Ideas & Extended Watchlist

Conatus Pharmaceuticals, Inc. CNAT

CNAT is a stock that we first discovered as an FDA play back in early December, when one of the company’s treatments had been granted orphan drug status.  At the time, the stock was trading at less than $5 a share, and by January, we saw a huge run that took it over $14.

It brought a few other swings in the following months, but had fallen to the back burner for quite some time as it consolidated. Yesterday it set off our alarms once again, springing back to life and running hard on heavy volume, so once again CNAT has our full attention.

After reaching as high as 9.90 during yesterday’s session, we’ll be on the lookout for possible dip-and-rip opportunities. We’d like to see support hold in the 8-8.50 range moving forward and if it can do that, chances to score quick strike gains on the bounce could be present.

Petroleo Brasiliero S.A. (Petrobras) PBR – Options

The PBR options chain has been a veritable cash cow for us this year as many of you already know, and we’ll continue to talk about it for as long as it continues to work in our favor. Yesterday was no letdown, as

All of the Call contracts that we’ve been monitoring ($14-15 Weekly Calls and the 07/19 $15 Calls) have been rocking, providing us with several shots at alarmingly high returns.

If PBR breaks over this morning’s pre-market high of 15.90, we may look to roll our strike price up to $16 (Possibly the 07/03 $16’s which closed @ .36 yesterday) and with how far the latest trend has taken us, we wouldn’t be too surprised to see that happen.

Extra Options Idea: Molson Coors Brewing Co. TAP

The TAP October $75 Calls showed an abnormal amount of trading activity yesterday, causing us to raise an eyebrow. Just for good measure, we’re going to throw those contracts up on our radar and monitor the situation.

Extended Watchlist:
KNDI, GERN, ZLCS, REPH, IDN, SNSS, SIGM, ARNA

Blue Horseshoe Stocks: ACHN, PBR & Extended Watchlist

Petroleo Brasiliero S.A. (Petrobras) PBR

PBR had another solid day yesterday, dipping below $15 only briefly where it found support at 14.88 before going on to push its upper limits over the course of the session, acvhieving a new high for us at 15.34.

All of the options contracts that we’ve been monitoring on PBR served up chances to gain a significant amount as the stock continued to bull its way north.

Even our longer-term idea, the 07/19 $15 Calls we’ve been tracking since last week from a low of .25 has already given us the triple-bagger we suggested it might in last Wednesday’s report. They closed out the day at .88, an overall move of 252% and it would appear they want to gap up along with PBR stock this morning, so we expect that figure to increase even further.

PBR has come a long way since we caught it coming off of 10-year lows back on March 21st. The stock itself has regained a lot of ground, coming from our observed low of 11.25 all the way up to current levels above $15. As we stated yesterday, if PBR has a tough time breaking through resistance at its previous swing high of 15.85, we’ll start to think about taking profits off of the table.

Achillion Pharmaceuticals, Inc. ACHN

We have to begin this morning by congratulating any of our readers who picked up on our coverage of ACHN yesterday, which allowed us the chance to make sizable gains for the second day in a row.

The stock gapped up as it did on Monday and continued to roll, trading in a range from 6.02 to 7.81 on the day, giving traders the opportunity to pocket close to 30% in profits intraday on inordinately high volume (To the tune of more than 22x the 3-month average).

From the low of 3.72 that we observed on Monday, the stock has already made a fantastic  110% move to the upside over the span of just two sessions.

The company put more news out this morning as well:

NEW HAVEN, Jun 11, 2014 (GLOBE NEWSWIRE via COMTEX) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at two upcoming investor conferences:– 2014 Wells Fargo Healthcare Conference on Wednesday, June 18, 2014 at 1:15 p.m. ET at the InterContinental Hotel in Boston, MA; and– JMP Health Care Conference 2014 on Tuesday, June 24, 2014 at 11:00 a.m. ET at the Westin New York Grand Central Hotel in New York, NY.

The live audio and subsequent archived webcasts of the Company’s presentations will be accessible from the Company’s investor relations website, http://ir.achillion.com.

Extended Watchlist:
NWBO, NAVB, BIOF, PEIX, END, XXII

Blue Horseshoe Stocks: PBR, ACHN, TMSH & More

Petroleo Brasiliero S.A. (Petrobras) PBR

We’ll kick things off this morning with PBR once again, as the stock had another banner day and behaved very much like we suggested it might. Yesterday we mentioned that the PBR chart was looking ripe for further northward movement and that’s just what we got.

The stock itself broke back over $15, which led to some prime opportunities in each and every set of options contracts that we outlined in our morning report. We said we’d be looking at Weekly Calls from $14-$15 for quick-flip intraday opportunities, and they all offered up some serious gains.

The $14 Calls traded from .74 to as high as 1.09, a chance for traders to score up to 47% in profits. The $14.50’s made a nice move up from .34 to .75, good for a nice double-bagger and more at +120% The $15’s fared extremely well also, running a whopping 290% from .11 up to .43.

Even our contracts of longer-term interest, the 07/19 $15 Calls (which we caught at a low of .25) made a solid intraday move from .54-.84, a highly respectable 55% increase.

All in all, for options traders, PBR was a paradise on Monday, and we’ll be continuously monitoring the situation as the week progresses. Major areas of resistance appear on the chart at 15.50 and 15.85, so failure to pierce through that channel would certainly be a signal to us to take profits off of the table. In order to keep our interest levels high, PBR will need to maintain support above the 15-dollar mark.

Achillion Pharmaceuticals, Inc. ACHN

Appearing in yesterday’s extended watchlist, ACHN was another play with potential to start off a new week. After a significant morning gap-up, the stock would touch a low of 3.72 before running as high as 4.82, an intraday move of 30%

This morning the company came with a well-timed release concerning its Hep-C drug, and the stock continues to blow its top. The high this morning in premarket trading is 6.47, making ACHN one that we’ll definitely be interested to follow. Per this morning’s PR, there’s a timeline for the testing of this drug leading all the way up to the end of the year, so we’ll stick ACHN on our longer-term radar as well.

NEW HAVEN, Jun 10, 2014 (GLOBE NEWSWIRE via COMTEX) — Initial cohort of HCV-infected patients begin dosing with ACH-3422 for seven days. Clinical trials may continue evaluating 200 mg of sovaprevir for HCV-infected patients. Timelines for reporting proof-of-concept results with ACH-3422, a proprietary uridine-analog nucleotide polymerase inhibitor, during the fall of 2014 and initiating all-oral combination studies by the end of 2014 remain on track >>> FULL PR

TransGlobal Assets, Inc. TMSH

We’ve been following TMSH since last week, and have not been disappointed. The stock has played out a textbook dip-and-rip scenario for the last three sessions straight, offering up many opportunities to make gains.

Yesterday, it came down as low as .0079 before ripping its way up to .0128, a healthy intraday increase of 62% Provided it continues to trade in this manner, we’ll be looking to take advantage of any similar swings to the ones we’ve seen already. We want to see it make higher lows, and break through the channel of resistance between the previous two sessions’ swing highs (.0128-.0139).

Side Note:

Even with so much else to talk about today, we can’t forget about another cash cow in Apple. AAPL Calls have been providing us with some excellent opportunities in recent weeks as well, and we’re still highly attuned to that situation as well.

Extended Watchlist:
DNAX, SPEX, AVNR, SGMS, ATEA, TPLM, KNDI